Introducing the 2019 American Association for the Study of Liver Diseases Guidance on Alcohol‐Associated Liver Disease by Lucey, Michael Ronan et al.
Introducing the 2019 American Association for the Study of Liver Diseases 
Guidance on Alcohol‐Associated Liver Disease 
Michael Ronan Lucey1, Gene Y. Im2, Jessica L. Mellinger3, Gyongyi Szabo4, David W. 
Crabb5. 
1. Division of Gastroenterology and Hepatology, University of Wisconsin School of
Medicine and Public Health, Madison, WI; 
2. Division of Liver Disease, Ichan School of Medicine at Mount Sinai, New York,
NY; 
3. Division of Gastroenterology, Department of Internal Medicine, University of
Michigan Hospital System, Ann Arbor, MI; 
4. Department of Medicine, University of Massachusetts Medical School,
Worcester, MA; and, 
5. Department of Medicine, Indiana University, Indianapolis, IN
____________________________________________________
This is the author's manuscript of the article published in final edited form as: 
Lucey, M. R., Im, G. Y., Mellinger, J. L., Szabo, G., & Crabb, D. W. (2020). Introducing the 2019 American 
Association for the Study of Liver Diseases Guidance on Alcohol-Associated Liver Disease. Liver Transplantation, 
26(1), 14–16. https://doi.org/10.1002/lt.25600
 
 
ABBREVIATIONS 
AASLD: American Association for the Study of Liver Diseases 
AC: alcohol‐associated cirrhosis 
AH: alcoholic hepatitis 
ALD: alcohol‐associated liver disease 
AUD: alcohol‐use disorder 
AUDIT: Alcohol Use Disorders Identification Test 
LT: liver transplantation 
MDF: Maddrey Discriminant Function 
MELD: Model for End‐Stage Liver Disease 
STOPAH: Steroids or Pentoxifylline for Alcoholic Hepatitis 
 
 
 
 
 
 
 
 
 
 
 
 
Published in 2010, the previous American Association for the Study of Liver Diseases 
(AASLD) practice guideline on alcoholic liver disease has been an undoubted success.1 
According to Google Scholar on June 14, 2019, it has received more than 1400 citations. 
 
 
In 2018, the AASLD Practice Guideline Committee decided that the field was ready for a 
new guideline, now called “a guidance.” We are the authors of the new guidance, which 
was published in Hepatology .2 In this brief review, we will summarize the new document 
and draw attention to the areas of change and controversy. The guidance statements are 
shown in bold. 
The new guidance is thematically different from the 2010 manuscript in that it places a 
heightened focus on alcohol‐use disorder (AUD) as the core feature of all alcohol‐
associated liver disease (ALD). We have learned from our colleagues in the world of 
addiction medicine of the negative role that stigma plays in exacerbating illnesses caused 
by excessive drinking. This recognition starts with the nomenclature adopted by the 
American Psychiatric Association in the most recent iteration of the Diagnostic and 
Statistics Manual of Mental Disorders , which dropped the term alcoholism in favor of 
AUD.3 Likewise, we have adopted the terms “alcohol‐associated liver disease” and 
“alcohol‐associated cirrhosis” while keeping the acronyms ALD and AC, respectively. We 
have retained alcoholic hepatitis (AH) because of common usage, but this, in time, may 
also fall out of use. These changes parallel those suggested by the most recent European 
Association for the Study of the Liver guidelines.4 
A focus on the nexus of AUD and ALD in our patient population is fundamental to all of 
our sections, beginning with screening for and diagnosis of AUD and the use of 
biomarkers of alcohol consumption. Thus, the first guidance statements are as follows: 
• All patients receiving care in primary care and gastroenterology/hepatology outpatient 
clinics, emergency departments, and inpatient admissions should be routinely 
screened for alcohol use using validated questionnaires. 
• Brief intervention, pharmacotherapy, and referral to treatment should be offered to 
patients engaged in hazardous drinking (Alcohol Use Disorders Identification Test 
[AUDIT]–C ≥4, AUDIT >8, binge drinkers). 
• Alcohol biomarkers can be used to aid in diagnosis and support recovery. Urine and 
hair ethyl glucuronide, urine ethyl sulfate, and phosphatidylethanol are not affected by 
liver disease, and therefore preferable. 
 
 
As in the previous guideline, abstinence from alcohol is the sine qua non of all treatment 
of AUD in patients with ALD. Heretofore, hepatologists and advanced practice providers 
(nurse practitioners and physician assistants) working in hepatology practices have not 
had the skill set to offer sophisticated assessment of and care for patients with ALD in 
combination with AUD. We believe that this is changing through the adoption of a 
multidisciplinary approach to management of AUD, particularly with embedded addiction 
specialists in the clinic.5 Consequently, our guidance reflects this new reality as follows: 
• Referral to AUD treatment professionals is recommended for patients with ALD and/or 
AUD in order to ensure access to the full range of AUD treatment options. 
• Multidisciplinary, integrated management of ALD and AUD is recommended and 
improves rates of alcohol abstinence among ALD patients. 
• Based on limited data, the use of acamprosate or baclofen can be considered for the 
treatment of AUD in patients with ALD. 
Finally, in relation to AUD, we offer specific guidance about drinking alcohol for patients, 
both with and without liver disease: 
• Patients without liver disease should be educated about safe levels of alcohol 
consumption for men (no more than 2 standard drinks per 24 hours) and women (no 
more than 1 standard drink per 24 hours). 
• Patients with ALD or other liver diseases, in particular nonalcoholic fatty liver disorder, 
nonalcoholic steatohepatitis, viral hepatitis, and hemochromatosis, should be counseled 
that there is no safe level of drinking and that they should abstain. 
Several more specific areas of change and controversy are considered in the new 
guidance, such as the characterization of the clinical forms of ALD, consideration of the 
methods for the diagnosis of ALD including the role of liver biopsy, and clarification of the 
definitions of AH and alcoholic steatohepatitis and acute‐on‐chronic liver failure in ALD.6 
The management of patients with severe AH remains controversial. Unfortunately, the 
past decade has not provided breakthrough advances in the medical management of AH, 
other than confirming the value of abstinence. However, our knowledge base has been 
enhanced by the Steroids or Pentoxifylline for Alcoholic Hepatitis (STOPAH) trial in the 
 
 
United Kingdom, which has clarified the limited role of corticosteroids, and by the Lille 
score, which has improved stopping rules for corticosteroids.7, 8 Our guidance for 
management of AH is as follows: 
• The clinical diagnosis of AH (definite, probable, possible) should be made using the 
published consensus criteria. 
• Laboratory‐based prognostic scores should be used to determine prognosis in AH. 
• The Maddrey Discriminant Function (MDF) (≥32) should be used to assess the need 
for treatment with corticosteroids or other medical therapies. 
• A Model for End‐Stage Liver Disease (MELD) score >20 also should prompt 
consideration of corticosteroid treatment. 
• Abstinence from alcohol should be promoted to improve longterm prognosis in AH. 
• Prednisolone 40 mg/day given orally should be considered to improve 28‐day mortality 
in patients with severe AH (MDF ≥32) without contraindications to the use of 
corticosteroids. 
• The addition of intravenous N ‐acetylcysteine to prednisolone 40 mg/day may improve 
the 30‐day survival of patients with severe AH. 
• The Lille score should be used to reassess prognosis, identify nonresponders, and 
guide treatment course after 7 days of corticosteroids. 
• Patients with AH should have malnutrition addressed and treated, preferably with 
enteral nutrition. 
• Pentoxifylline is no longer recommended in the treatment of AH. 
The 2010 AASLD guideline on ALD concluded with a short section on liver transplantation 
(LT), which, while acknowledging that LT was appropriate in carefully selected ALD 
subjects, also stated that a 6‐month period of abstinence was recommended as a 
prerequisite to placement on the LT waiting list. The latter statement precluded LT as a 
treatment of life‐threatening AH not responding to medical management. Since then, a 
prospective European pilot study and a retrospective multicenter American study have 
shown good to excellent early results of LT in selected patients with life‐threatening AH 
and recent alcohol use.9, 10 We are still in the early stages of understanding how best to 
apply LT in patients with AH, and many unanswered questions remain about patient 
 
 
selection, treatment of AUD after LT, and longer‐term outcomes. In this fluid situation, we 
made the following guidance statements: 
• Patients with decompensated AC, Child‐Turcotte‐Pugh C, or MELD‐sodium ≥21 should 
be referred and considered for LT. 
• Candidate selection for LT in AC should not be solely based on a fixed interval of 
abstinence. 
LT may be considered in carefully selected patients with favorable psychosocial profiles 
in severe AH not responding to medical therapy. 
 
Finally, our document looks to the future and identifies the gaps in our knowledge that are 
ripe for further study: 
1. Studies providing the accurate assessment of the prevalence of ALD, particularly 
identifying earlier asymptomatic stages of ALD, such as alcohol‐associated steatosis 
or moderate AH, are needed and may become feasible with broader use of noninvasive 
steatosis and fibrosis assessment tools. 
2. Well‐constructed studies of the incidence of AH in the United States are needed. 
Particular attention should be paid to diversity of sex, racial background, and age. 
3. ALD patients have been omitted from studies of efficacy of treatments for AUD. Studies 
are needed to assess the efficacy of psychosocial and pharmacological treatments in 
initiating and maintaining abstinence by patients with ALD. 
4. The potential for serial measurements of biomarkers in patients with ALD are needed, 
with the dual endpoints of abstinence and stabilization or improvement in liver disease. 
5. Studies of medical agents that abrogate the pathophysiological mechanisms that lead 
to chronic alcohol‐associated liver injury are needed. These processes include chronic 
inflammation, the role of the gut microbiota, progressive fat accumulation, and 
progressive fibrotic injury. 
6. New clinical trials are needed both in moderate (MELD ≤20) and severe AH (MELD 
>20) to improve the management of AH. 
 
 
7. Prospective clinical studies of the utility of LT in selected patients with severe AH are 
needed. In particular, areas for investigation include processes of patient selection, 
monitoring alcohol use before and after LT, and treatment of AUD before and after LT. 
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Correction statement: Correction added on December 20, 2019, after initial online 
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